Arena Pharma (ARNA) Stock Buy Rating Kept at Cantor Fitzgerald; The Target Price per Share Given is $65.0000; Moore Capital Management LP Decreased Expedia Del (EXPE) Stake By $23.21 Million

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

Cantor Fitzgerald have a $65.0000 target price per share on the stock. The target price per share would indicate a potential upside of 66.03% from Arena Pharma (NASDAQ:ARNA)‘s last stock close. This rating was disclosed to clients in a research note on Wednesday morning.

Moore Capital Management Lp decreased Expedia Inc Del (EXPE) stake by 70.91% reported in 2017Q4 SEC filing. Moore Capital Management Lp sold 195,000 shares as Expedia Inc Del (EXPE)’s stock declined 12.14%. The Moore Capital Management Lp holds 80,000 shares with $9.58 million value, down from 275,000 last quarter. Expedia Inc Del now has $16.74B valuation. The stock decreased 0.15% or $0.17 during the last trading session, reaching $110.28. About 1.42M shares traded. Expedia Group, Inc. (NASDAQ:EXPE) has declined 17.38% since April 19, 2017 and is downtrending. It has underperformed by 28.93% the S&P500.

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on May, 8. They expect $-0.70 EPS, up 22.22% or $0.20 from last year’s $-0.9 per share. After $-0.36 actual EPS reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 94.44% negative EPS growth.

Among 10 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Arena Pharmaceuticals has $64.0 highest and $2 lowest target. $40.56’s average target is 3.60% above currents $39.15 stock price. Arena Pharmaceuticals had 25 analyst reports since October 28, 2015 according to SRatingsIntel. The rating was maintained by Citigroup on Tuesday, February 27 with “Buy”. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, November 8 report. On Tuesday, March 20 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Monday, February 26. Cantor Fitzgerald has “Buy” rating and $45.0 target. The stock has “Buy” rating by Needham on Tuesday, March 20. Leerink Swann maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, January 17. Leerink Swann has “Buy” rating and $56.0 target. The firm has “Outperform” rating by FBR Capital given on Thursday, September 15. The firm has “Buy” rating given on Thursday, January 4 by Cantor Fitzgerald. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, July 11 report. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, July 19 report.

The stock increased 5.73% or $2.12 during the last trading session, reaching $39.15. About 1.35M shares traded or 0.72% up from the average. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 169.40% since April 19, 2017 and is uptrending. It has outperformed by 157.85% the S&P500.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.92 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Among 42 analysts covering Expedia Inc. (NASDAQ:EXPE), 28 have Buy rating, 0 Sell and 14 Hold. Therefore 67% are positive. Expedia Inc. had 130 analyst reports since July 24, 2015 according to SRatingsIntel. Morgan Stanley maintained Expedia Group, Inc. (NASDAQ:EXPE) rating on Friday, February 9. Morgan Stanley has “Overweight” rating and $150 target. JP Morgan maintained Expedia Group, Inc. (NASDAQ:EXPE) rating on Monday, February 12. JP Morgan has “Neutral” rating and $115 target. The company was maintained on Thursday, October 26 by KeyBanc Capital Markets. Cowen & Co maintained it with “Buy” rating and $140.0 target in Wednesday, March 21 report. The stock of Expedia Group, Inc. (NASDAQ:EXPE) earned “Hold” rating by Stifel Nicolaus on Friday, February 9. On Friday, February 9 the stock rating was maintained by Citigroup with “Buy”. Piper Jaffray maintained it with “Buy” rating and $17300 target in Friday, July 28 report. As per Thursday, December 7, the company rating was downgraded by M Partners. Credit Suisse maintained Expedia Group, Inc. (NASDAQ:EXPE) rating on Friday, October 27. Credit Suisse has “Neutral” rating and $147 target. On Thursday, November 5 the stock rating was upgraded by Oppenheimer to “Outperform”.

Analysts await Expedia Group, Inc. (NASDAQ:EXPE) to report earnings on April, 26 after the close. They expect $-0.75 EPS, down 400.00% or $0.60 from last year’s $-0.15 per share. After $0.64 actual EPS reported by Expedia Group, Inc. for the previous quarter, Wall Street now forecasts -217.19% negative EPS growth.

Moore Capital Management Lp increased Spdr S&P 500 Etf Tr (Call) (SPY) stake by 2.40 million shares to 3.40 million valued at $907.32M in 2017Q4. It also upped Apple Inc (NASDAQ:AAPL) stake by 900,000 shares and now owns 1.18M shares. Canadian Pac Ry Ltd (NYSE:CP) was raised too.

Expedia Group, Inc. (NASDAQ:EXPE) Institutional Positions Chart